WCN26-5713 Effectiveness and safety of telitacicept in recurrent IgA nephropathy after kidney transplantation

Read full text Summarise with VIRAT
Authors: Shaohua Shi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Immunoglobulin A nephropathy (IgAN) is frequently recurrent after kidney transplantation, posing significant challenges in management. Telitacicept reduces B cell activation and abnormal immunoglobulin A (IgA) antibody production by inhibiting the activity of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby decreasing IgA deposition in he glomeruli and local inflammatory response. This ultimately protects the kidneys from damage.A phase 2 clinical trial indicated that telitacicept could reduce proteinuria in patients with primary IgAN.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments Complement system in diseases

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105503–105503
Publication date
25 March 2026
Language
EN